{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:56:17Z","timestamp":1793422577374,"version":"4.5.0"},"reference-count":15,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) perturb T-cell regulatory pathways to enhance antitumor immunity. However, an increase reporting of ICI-associated diabetes is observed in adults. To our knowledge, no cases have been reported in the pediatric population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>We describe a pediatric case of ICI-associated type 1 diabetes in a 12-year-old Hispanic boy with Hodgkin lymphoma. The patient had a history of autologous hematopoietic stem cell transplantation and was treated with pembrolizumab after disease progression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The patient was admitted for diabetic ketoacidosis after five cycles of pembrolizumab. The patient was discharged with daily insulin injections and has continued on exogenous insulin ever since.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The expanded ICI use may lead to more cases in pediatric patients as has been observed in adults. Considering the acute manifestation of diabetes and the added burden of lifelong insulin therapy, in particular for pediatric patients and their families, monitoring and education of ICI-associated diabetes in children is needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc20-0740","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T23:55:13Z","timestamp":1593734113000},"page":"2293-2295","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":25,"title":["Anti\u2013PD-1 Therapy\u2013Associated Type 1 Diabetes in a Pediatric Patient With Relapsed Classical Hodgkin Lymphoma"],"prefix":"10.2337","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7208-8764","authenticated-orcid":false,"given":"Raynald A.","family":"Samoa","sequence":"first","affiliation":[{"name":"Department of Clinical Diabetes, Endocrinology & Metabolism, Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley S.","family":"Lee","sequence":"additional","affiliation":[{"name":"Diabetes & Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung H.","family":"Kil","sequence":"additional","affiliation":[{"name":"Diabetes & Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1616-8337","authenticated-orcid":false,"given":"Bart O.","family":"Roep","sequence":"additional","affiliation":[{"name":"Department of Diabetes Immunology, Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"key":"2022031223565052900_B1","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.2337\/dc18-1465","article-title":"Increased reporting of immune checkpoint inhibitor-associated diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031223565052900_B2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2022031223565052900_B3","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"2022031223565052900_B4","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2022031223565052900_B5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"2022031223565052900_B6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/cei.12603","article-title":"Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes","volume":"180","author":"Fujisawa","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"2022031223565052900_B7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"2022031223565052900_B8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/dc19-0880","article-title":"Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes","volume":"43","author":"Battaglia","year":"2020","journal-title":"Diabetes Care"},{"key":"2022031223565052900_B9","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031223565052900_B10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fimmu.2018.00767","article-title":"Resetting the T cell compartment in autoimmune diseases with autologous hematopoietic stem cell transplantation: an update","volume":"9","author":"Lutter","year":"2018","journal-title":"Front Immunol"},{"key":"2022031223565052900_B11","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1172\/JCI71691","article-title":"T cell repertoire following autologous stem cell transplantation for multiple sclerosis","volume":"124","author":"Muraro","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031223565052900_B12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","article-title":"Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system","volume":"113","author":"Alexander","year":"2009","journal-title":"Blood"},{"key":"2022031223565052900_B13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2017.00167","article-title":"Immunological balance is associated with clinical outcome after autologous hematopoietic stem cell transplantation in type 1 diabetes","volume":"8","author":"Malmegrim","year":"2017","journal-title":"Front Immunol"},{"key":"2022031223565052900_B14","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3389\/fimmu.2018.00690","article-title":"A future for autologous hematopoietic stem cell transplantation in type 1 diabetes","volume":"9","author":"van Megen","year":"2018","journal-title":"Front Immunol"},{"key":"2022031223565052900_B15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2019.12.029","article-title":"ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients","volume":"127","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/9\/2293\/630326\/dc200740.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/9\/2293\/630326\/dc200740.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T03:55:12Z","timestamp":1647143712000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/43\/9\/2293\/35938\/Anti-PD-1-Therapy-Associated-Type-1-Diabetes-in-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,7,2]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc20-0740","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]}}}